- Home
- HKD vs KALV Comparison
HKD vs KALV Comparison
Compare HKD & KALV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | HKD | KALV |
|---|---|---|
| Founded | 2003 | N/A |
| Country | France | United States |
| Employees | N/A | N/A |
| Industry | Finance: Consumer Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 487.1M | 551.2M |
| IPO Year | 2022 | N/A |
Fundamental Metrics
Financial Performance| Metric | HKD | KALV |
|---|---|---|
| Price | $1.36 | $15.79 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 6 |
| Target Price | N/A | ★ $27.17 |
| AVG Volume (30 Days) | 411.8K | ★ 1.4M |
| Earning Date | 02-27-2026 | 11-10-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $87,436,000.00 | $1,426,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $204.16 |
| P/E Ratio | $11.67 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $1.33 | $7.30 |
| 52 Week High | $5.47 | $17.30 |
Technical Indicators
Market Signals| Indicator | HKD | KALV |
|---|---|---|
| Relative Strength Index (RSI) | 40.06 | 57.04 |
| Support Level | $1.33 | $14.70 |
| Resistance Level | $1.43 | $16.30 |
| Average True Range (ATR) | 0.07 | 0.88 |
| MACD | -0.00 | -0.18 |
| Stochastic Oscillator | 11.55 | 40.96 |
Price Performance
Historical ComparisonAbout HKD AMTD Digital Inc. (every five of which represent two)
AMTD Digital Inc along with its subsidiaries, is mainly involved in the provision of digital solutions services. Its reportable segments are digital solutions services segment, hotel operations, hospitality and VIP services segment and media and entertainment services. The company generates maximum revenue by providing financial digital solutions through its insurance brokerage services and other digital solutions services. Geographically, the company generates maximum revenue from Hong Kong and Singapore.
About KALV KalVista Pharmaceuticals Inc.
KalVista Pharmaceuticals Inc is a pharmaceutical company developing and delivering oral therapies for individuals affected by rare diseases with unmet needs. The company applies its knowledge in the kallikrein-kinin system (KKS) and oral drug discovery to develop small-molecule protease inhibitor medicines to address the needs of patients with diseases driven by plasma kallikrein and Factor XIIa. Its FDA-approved product EKTERLY (sebetralstat) is a novel, orally delivered, small-molecule plasma kallikrein inhibitor for the treatment of acute attacks of hereditary angioedema (HAE) in adult and pediatric patients aged twelve years and older.